Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)

HKG:3378 Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023
Period Ending	Feb 12, 2026	Dec 31, 2024	Dec 31, 2023
Debt / Equity Ratio	0.06	0.06	0.05
Net Debt / Equity Ratio	-0.75	-0.75	-0.59
Net Debt / EBITDA Ratio	1.39	1.39	3.11
Net Debt / FCF Ratio	1.46	1.46	3.37
Asset Turnover	0.00	0.00	-
Quick Ratio	0.88	0.88	3.25
Current Ratio	1.23	1.23	4.75
Return on Equity (ROE)	-43.61%	-43.61%	-
Return on Assets (ROA)	-13.64%	-13.64%	-
Return on Capital Employed (ROCE)	-39.00%	-39.00%	-11.70%
Buyback Yield / Dilution	-	-49.83%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.